Premium
Treatment of hypokalemic periodic paralysis with topiramate
Author(s) -
Fiore Darren M.,
Strober Jonathan B.
Publication year - 2011
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.21854
Subject(s) - topiramate , hypokalemic periodic paralysis , paralysis , endocrinology , medicine , periodic paralysis , muscle weakness , hypokalemia , weakness , carbonic anhydrase , epilepsy , biology , surgery , enzyme , biochemistry , psychiatry
Hypokalemic periodic paralysis (hypoPP), the most common form of periodic paralysis, is a disorder characterized by attacks of transient muscle weakness associated with a drop in serum potassium level.The mainstay of treatment is potassium supplementation and drugs that inhibit the enzyme carbonic anhydrase. In this report we describe 11‐year‐old twins with hypoPP who were treated with topiramate, an anti‐epileptic drug known to have carbonic anhydrase inhibitory properties. The patients experienced a decrease in the severity of their attacks upon initiation of treatment. Topiramate may warrant further investigation as a treatment option in hypoPP. Muscle Nerve, 2011